{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-107727","form_type":"8-K","ticker":"NTRA","cik":"0001604821","company_name":"Natera, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.898185+00:00","generated_at":"2026-05-16T23:42:38.844020+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Natera Q3 revenue up 35% to $592M; raises FY2025 guidance by $160M midpoint","bullets":["Revenue $592.2M (+34.7% YoY); product rev +35.3%; gross margin 64.9% vs 61.8%.","Oncology tests 211,000 (+53.9% YoY); record MRD sequential growth of ~21,500 units.","Positive cash flow $26.4M in Q3; net loss $(0.64)/share vs $(0.26) YoY.","Raises FY2025 revenue guidance to $2.18B-2.26B from $2.02B-2.10B.","FY2025 guidance: gross margin ~62-64%; net cash inflow ~$100M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-107727","json":"https://secwatch.observer/filing/0001104659-25-107727.json","markdown":"https://secwatch.observer/filing/0001104659-25-107727.md","text":"https://secwatch.observer/filing/0001104659-25-107727.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604821/000110465925107727/0001104659-25-107727-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604821/000110465925107727/tm2529763d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:42:38.844020+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}